| Indicators | Browse All

Monopar Therapeutics Inc. (MNPR)

Healthcare | Biotechnology | Wilmette, United States | NasdaqCM
103.33 USD -3.27 (-3.068%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 104.00 +0.67 (0.648%) ⇧ (July 13, 2026, 4:25 p.m. EDT)

Short-term:★★★★⯪Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:19 a.m. EDT

The short-term outlook is aggressively bullish due to a massive technical breakout. The stock has surged from the $36 range to over $106 in a single year, shattering the 52-week high and trading significantly above both its 50-day and 200-day moving averages. This momentum is reinforced by a 'strong buy' consensus from analysts and positive headlines regarding the improved bull case for its lead drug candidate. However, the long-term investment thesis remains fundamentally flawed despite the price explosion. The company is burning cash, with negative free cash flow and negative returns on equity and assets, while still reporting losses. The balance sheet, while currently debt-light, relies entirely on capital markets to fund operations. The recent price surge appears to be a speculative event driven by catalyst anticipation rather than a resolution of these deep operational deficits. Consequently, while the immediate trend is upward, the underlying business quality does not yet support a permanent long-term hold at these valuations.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.164832
MSTL0.181344
AutoETS0.187130
AutoTheta0.188031

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 26%
H-stat 17.29
Ljung-Box p 0.000
Jarque-Bera p 0.003
Excess Kurtosis 0.49
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.17
Market Cap 692,214,080
Forward P/E -32.93
Beta 1.48
Website https://www.monopartx.com

Info Dump

Attribute Value
52 Week Change 1.4376857
Address1 1,000 Skokie Boulevard
Address2 Suite 350
All Time High 240.0
All Time Low 1.37
Ask 102.4
Ask Size 6
Audit Risk 9
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 195,950
Average Daily Volume3 Month 172,645
Average Volume 172,645
Average Volume10Days 195,950
Beta 1.475
Bid 104.31
Bid Size 1
Board Risk 10
Book Value 20.595
City Wilmette
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 10
Country United States
Crypto Tradeable 0
Currency USD
Current Price 103.33
Current Ratio 56.045
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 106.66
Day Low 100.505
Debt To Equity 0.17
Display Name Monopar Therapeutics
Earnings Timestamp 1,778,785,200
Earnings Timestamp End 1,786,647,600
Earnings Timestamp Start 1,786,647,600
Ebitda Margins 0.0
Enterprise Value 554,951,552
Eps Current Year -2.90373
Eps Forward -3.1375
Eps Trailing Twelve Months -1.93
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 69.6448
Fifty Day Average Change 33.685204
Fifty Day Average Change Percent 0.4836715
Fifty Two Week Change Percent 143.76857
Fifty Two Week High 112.57
Fifty Two Week High Change -9.239998
Fifty Two Week High Change Percent -0.08208224
Fifty Two Week Low 29.18
Fifty Two Week Low Change 74.15
Fifty Two Week Low Change Percent 2.541124
Fifty Two Week Range 29.18 - 112.57
Financial Currency USD
First Trade Date Milliseconds 1,576,765,800,000
Float Shares 4,117,444
Forward Eps -3.1375
Forward P E -32.933865
Free Cashflow -5,376,986
Full Exchange Name NasdaqCM
Full Time Employees 22
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.23417
Held Percent Institutions 0.93299
Implied Shares Outstanding 6,699,062
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,723,507,200
Last Split Factor 1:5
Long Business Summary Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Long Name Monopar Therapeutics Inc.
Market us_market
Market Cap 692,214,080
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_304391755
Most Recent Quarter 1,774,915,200
Net Income To Common -14,984,972
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 714,120,009
Number Of Analyst Opinions 13
Open 103.28
Operating Cashflow -10,011,881
Operating Margins 0.0
Overall Risk 9
Payout Ratio 0.0
Phone 847 388 0349
Post Market Change 0.66999817
Post Market Change Percent 0.6484062
Post Market Price 104.0
Post Market Time 1,783,974,329
Previous Close 106.6
Price Eps Current Year -35.585266
Price Hint 2
Price To Book 5.0172377
Profit Margins 0.0
Quick Ratio 55.943
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.30769
Region US
Regular Market Change -3.27
Regular Market Change Percent -3.06754
Regular Market Day High 106.66
Regular Market Day Low 100.505
Regular Market Day Range 100.505 - 106.66
Regular Market Open 103.28
Regular Market Previous Close 106.6
Regular Market Price 103.33
Regular Market Time 1,783,972,801
Regular Market Volume 214,315
Return On Assets -0.121120006
Return On Equity -0.15858
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 2
Shares Outstanding 6,699,062
Shares Percent Shares Out 0.22690001
Shares Short 1,519,701
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 1,579,320
Short Name Monopar Therapeutics Inc.
Short Percent Of Float 0.3323
Short Ratio 10.11
Source Interval 15
State IL
Symbol MNPR
Target High Price 130.0
Target Low Price 100.0
Target Mean Price 113.61538
Target Median Price 115.0
Total Cash 137,492,944
Total Cash Per Share 20.524
Total Debt 230,425
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.93
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 69.49898
Two Hundred Day Average Change 33.831024
Two Hundred Day Average Change Percent 0.4867845
Type Disp Equity
Volume 214,315
Website https://www.monopartx.com
Zip 60,091